Volition Webinar: Unraveling the web of NETs in sepsis

VolitionRX is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. In this webinar, intensive care specialist and haematology key opinion leader Dr Andrew Retter helps us understand: the burden of sepsis and challenges in treatment and patient care; the connection between NETosis and sepsis; the future of tools and treatments, as well as the potential role of NETs in other disease areas; and the role of Volition’s diagnostics tools to address unmet need in the space. Leading the panel and Q&A session is Soo Romanoff, Managing Director of Healthcare at Edison Group.